Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1817-1822

  Jánosi, Judit ^a   Sebestyén, Anna ^b   Bocsi, József ^b   Barna, Gábor ^b   Nagy, Katalin ^b   Vályi Nagy, István ^a   Kopper, László ^b  

^a NATIONAL MEDICAL CENTER   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Apoptosis; Caspase; Mevastatin; Multiple myeloma

Indexed keywords

CASPASE; CASPASE 8; COMPACTIN; FAS ANTIBODY; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; NEUTRALIZING ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; LOVASTATIN; MULTIPLE MYELOMA;

EID: 3242691569     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
2. Cox AD and Der CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply RAS. Biochim Biophys Acta 1333: F51-F71, 1997.
3. Agarwal B, Rao CV, Bhesalwal S, Ramey WR, Shirin H, Reddy BS and Holter R: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemoprotective effect of sulindac. Gastroenterology 117: 838-847, 1999.
4. Korman L and Borysink L: Replacing lovastatin with pravastatin: effect on serum lipids and cost. Am J Health Syst Pharm 52: 1078-1082, 1995.
5. Alberts AW: Discovery, biochemistry and biology of lovastatin. Amer J Cardiol 62: 10J-15J, 1988.
6. Jakobiosal M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effect of lovastatin. Proc Nat Acid Sci (Wash) 88: 3628-3632, 1991.
7. Sumi S, Beauchamp Rd, Townsend CM, Pour PM and Ishazuka J: Lovastatin inhibits pancreatic cell growth of RAS mutation. Pancreas 5: 657-661, 1994.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleen JL, Rutherford JD, Cole TG, Brown L et al: The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol level. Cholesterol and Recurrent Event Trial Investigators. N England J Med 335: 1001-1009, 1996.
9. Pederson TR, Berge K, Cook TJ, Faergeman O, Haghfelt T and Kjekstus J: Safety and tolarability of cholesterol lowering agents with simvastatin during 5 years in Scandinavian Simvastatin Survival Study. Arch Intern Med 156: 3085-3092, 1996
10. Fischer DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
11. Kroemer G, Dallaporta B and Resche-Rigon M: The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619-642, 1998
12. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
13. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
14. Wickremosingle RG and Hoffbrand AV: Biochemical and genetic control of apoptosis relevance to normal haematopoesis and haematological malignancies. Blood 93: 3587-3600, 1999.
15. Nashimoto N, Shina Y, Yoshizaki K and Kishimoto T: Myeloma biology and therapy: present status and future developments. Haematol Oncol Clin North Am 11: 159-172, 1997.
16. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J et al: BCL-XL expression in multiple myeloma, possible indicator of chemoresistance. Cancer Res 58: 256-262, 1998.
17. Wachtershauser A, Akoglen B and Stein J: HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line CaCo2. Carcinogenesis 22: 1061-1067, 2001.
18. van de Donk NW, Kamphuis MM, Lakhorsz HM and Bloem Ac: The cholesterol lowering drug lovastatin induced cell death in myeloma plasma cells. Leukemia 16: 1362-1371, 2002.
19. Park C, Lee I and Kang WK: Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 10: 1727-1731, 2001.
20. Xia Z, Tan M, Wong WW, Dimitroulakos J, Minden MD and Penn LZ: Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 9: 1398-1407, 2001.
21. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H et al: 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastatis. Gastroenterology 122: 308-317, 2002.
22. Agarwal B, Halmos B, Moss SF, Ramey WG and Holter PR: Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents. Proc Am Assoc Cancer Res 39: 68, 1998.
23. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW and Minden MD: Lovastatin induces a pronounced differentation response acute myeloid leukemia. Leuk Lymphoma 40: 167-178, 2000.
24. Wong WW, Dimittroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell:the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002.
25. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC and Treon SP: Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99: 2162-2171, 2002.
26. Ridley R, Xiao H, Hata H, Woodliff J, Epstein J and Sanders R: Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81: 767-774, 1993.
27. Wijdenes J, Vooijis WC, Clement C et al: A plasmocyte selective monoclonal antibody/B-B4 recognizes syndecan-1. Br J Haematol 94: 318-323, 1996.
28. Dhodapkar M, Abe E, Theus A, Lacy M, Langford K, Borlogie B et al: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor survival, growth and bone cell differentation. Blood 91: 2679-2688, 1998.
29. Thibault A, Samid D, Tompkins AC, Fiff WD, Cooper MR, Hohl RJ et al: Phase I study of lovastatin, an inhibitor of the mevalonat pathway, in patients with cancer. Clin Cancer Res 2: 483-491, 1996.
30. Kim WS, Kim HM, Choi HJ, Yonn SS, Lee HM, Park K et al: Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19: 81-83, 2001.
31. Minden MD, Dimitroulakos J, Notrynek D and Penn LZ: Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40: 659-662, 2001.
32. Kawata S, Yamasaki E, Naogese E, Inui Y, Ito N, Matsuda Y et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001.